Bleomycin Toxicity - Findings on FDG PET CT.

Area of Science:

• Oncology
• Radiology
• Pulmonology

Background:

• Bleomycin is a crucial chemotherapy agent for curable cancers like Hodgkin Lymphoma.
• Bleomycin lung toxicity (BLT) is a significant dose-limiting side effect.
• Early intervention is key, as BLT is reversible only in its initial inflammatory stages.

Purpose of the Study:

• To evaluate the efficacy of 18F Flourodeoxyglucose (FDG) PET-CT in predicting early bleomycin lung toxicity (BLT).
• To determine if FDG PET-CT can identify lung changes indicative of BLT before clinical manifestation.

Main Methods:

• Utilized 18F Flourodeoxyglucose (FDG) PET-CT imaging.
• Monitored lung parenchymal uptake on interim and end-of-treatment scans.
• Correlated imaging findings with clinical presentation and diagnosis of BLT.

Main Results:

• FDG PET-CT demonstrated potential in predicting BLT early in the treatment course.
• Increased lung parenchymal uptake on scans indicated a risk of BLT.
• FDG PET-CT identified potential BLT even without visible morphological lung abnormalities or symptoms.

Conclusions:

• 18F Flourodeoxyglucose (FDG) PET-CT is a valuable tool for the early prediction of bleomycin lung toxicity.
• Routine monitoring of lung uptake on PET-CT scans is recommended for patients receiving bleomycin.
• This imaging modality may facilitate timely treatment and improve outcomes for patients at risk of BLT.